Kaken Pharmaceutical said on June 5 that it filed for Japanese regulatory approval of its head lice treatment ivermectin, licensed from US-based Arbor Pharmaceuticals and sold as Sklice Lotion in the US. Development of the product began in 2019 after…
To read the full story
Related Article
- Kaken’s Head Lice Lotion Hits PIII Goal, Filing Eyed in 1st Half of FY2026
December 9, 2025
- Kaken Grabs Japan Rights to Arbor’s Head Lice Drug
March 1, 2019
BUSINESS
- Argenx Steps Up Japan Hunt for Drug Discovery Seeds
October 7, 2026
- Asahi Kasei Therapeutics Reports Potential Data Breach Affecting 560,000
October 7, 2026
- Toho Files Objection to Court Block on Takeover Defense Move
October 7, 2026
- Keytruda Marks 3 Years at No. 1 in September: Encise
October 7, 2026
- Shionogi to Offload Allergy Drug Actair to Ceolia
October 7, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…





